Top Markets
Coin of the day
Organogenesis Holdings Inc. Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGO
Classement en actions #17992
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Prix de l'action
$1.69
Dernière synchronisation: 2026-09-02
Capitalisation boursière
$216.83M
Changement (1 jour)
3.38%
Changement (1 an)
-66.03%
Pays
US
Échange Organogenesis Holdings Inc. (ORGO)

Catégorie

Marge opérationnelle de Organogenesis Holdings Inc. (ORGO)
Marge opérationnelle au 2026 TTM : 0.00%
Selon les derniers rapports financiers et le cours de l'action de Organogenesis Holdings Inc., la marge opérationnelle actuelle (TTM) est de 0.00%. À la fin de 2026, elle était de 0.00%.
Historique de la marge opérationnelle pour Organogenesis Holdings Inc. de 2026 à 2026
Marge opérationnelle à la fin de chaque année
Année Marge opérationnelle Changez
Pas assez de données pour les dates fournies.
Marge opérationnelle pour des entreprises similaires ou concurrentes
Entreprise Marge opérationnelle Différence de Marge Opérationnelle Pays
0.00% -
DE
0.00% -
DE
0.00% -
JP
22.93% -
IN
0.00% -
CH
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.